MX2017009889A - Vacuna a base del citomegalovirus, expresando la glicoproteína del virus del ébola. - Google Patents

Vacuna a base del citomegalovirus, expresando la glicoproteína del virus del ébola.

Info

Publication number
MX2017009889A
MX2017009889A MX2017009889A MX2017009889A MX2017009889A MX 2017009889 A MX2017009889 A MX 2017009889A MX 2017009889 A MX2017009889 A MX 2017009889A MX 2017009889 A MX2017009889 A MX 2017009889A MX 2017009889 A MX2017009889 A MX 2017009889A
Authority
MX
Mexico
Prior art keywords
cytomegalovirus
ebola virus
based vaccine
virus glycoprotein
vaccine expressing
Prior art date
Application number
MX2017009889A
Other languages
English (en)
Inventor
Aoife Murphy Aisling
marzi Andrea
arthur jarvis Michael
Feldmann Heinrich
Messaoudi POWERS Ilhem
Original Assignee
Univ Plymouth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Plymouth filed Critical Univ Plymouth
Publication of MX2017009889A publication Critical patent/MX2017009889A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Un vector basado en herpesvirus recombinante que comprende una secuencia de ácido nucleico que codifica un antígeno heterólogo y un promotor para controlar la expresión del antígeno, en el que el promotor se expresa en un momento seleccionado para proporcionar una respuesta inmune requerida en un sujeto.
MX2017009889A 2015-01-30 2016-01-28 Vacuna a base del citomegalovirus, expresando la glicoproteína del virus del ébola. MX2017009889A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1501523.3A GB201501523D0 (en) 2015-01-30 2015-01-30 Differential immune response modulation
PCT/EP2016/051854 WO2016120415A1 (en) 2015-01-30 2016-01-28 Cytomegalovirus-based vaccine expressing ebola virus glycoprotein

Publications (1)

Publication Number Publication Date
MX2017009889A true MX2017009889A (es) 2019-02-20

Family

ID=52705478

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009889A MX2017009889A (es) 2015-01-30 2016-01-28 Vacuna a base del citomegalovirus, expresando la glicoproteína del virus del ébola.

Country Status (6)

Country Link
US (1) US20180021425A1 (es)
EP (1) EP3250231A1 (es)
CN (1) CN108367064A (es)
GB (1) GB201501523D0 (es)
MX (1) MX2017009889A (es)
WO (1) WO2016120415A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201514034D0 (en) * 2015-08-08 2015-09-23 Univ Plymouth Improvements in or relating to DNA recombination
WO2021014398A1 (en) 2019-07-23 2021-01-28 University Of Rijeka Faculty Of Medicine Integrated human cytomegalovirus / glioblastoma vaccine
GB2594520A (en) 2020-05-01 2021-11-03 Quanta Dialysis Technologies Ltd Portable dialysis system
GB2596811A (en) 2020-07-06 2022-01-12 Quanta Dialysis Technologies Ltd Dialysis system

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4627950B2 (ja) * 1999-12-23 2011-02-09 アメリカ合衆国 変異ＨＩＶｇａｇ／ｐｏｌ、ＳＩＶｇａｇおよびＳＩＶｅｎｖ遺伝子を持つ分子クローン
PL2163260T3 (pl) * 2004-01-23 2017-12-29 Msd Italia S.R.L. Szympansie adenowirusowe nośniki szczepionek
CA2837748C (en) * 2004-05-25 2016-03-08 Oregon Health And Science University Siv and hiv vaccination using rhcmv-and hcmv-based vaccine vectors
EP2569436B8 (en) * 2010-05-14 2019-10-30 Oregon Health & Science University Recombinant hcmv and rhcmv vectors and uses thereof

Also Published As

Publication number Publication date
CN108367064A (zh) 2018-08-03
EP3250231A1 (en) 2017-12-06
GB201501523D0 (en) 2015-03-18
WO2016120415A1 (en) 2016-08-04
US20180021425A1 (en) 2018-01-25

Similar Documents

Publication Publication Date Title
MX2017002791A (es) Vacuna contra filovirus de virus vaccinia ankara modificado (mva) recombinante.
MX2018007237A (es) Proteinas de cápside modificadas para un suministro mejorado de vectores de parvovirus.
PH12017501115A1 (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and method of use
IL249903A0 (en) Recombinant Listeria strain expressing heterologous antigenic chimeric proteins and methods of using the same
WO2016168728A3 (en) Recombinant promoters and vectors for protein expression in liver and use thereof
MX2015012454A (es) Vectores que comprenden secuencias de polinucleotidos rellenadoras/de relleno y metodos de uso.
MX2017005661A (es) Celulas de mamifero que expresan antigenos de citomegalovirus.
MX361893B (es) Vectores recombinantes de herpesvirus 3 galido (mdv serotipo 2) que expresan antigenos de patogenos de aves y sus usos.
EP3012322A4 (en) GENEELED STRAIN VARIANT OF PORCINE PSEUDORABIES VIRUS, VACCINE COMPOSITION, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF
NZ628213A (en) Adenoviruses expressing heterologous tumor-associated antigens
EA201692025A1 (ru) Доставка белков, осуществляемая на основе бактерий
MY173638A (en) Parainfluenza virus 5 based vaccines
MX2017009889A (es) Vacuna a base del citomegalovirus, expresando la glicoproteína del virus del ébola.
MX2020003508A (es) Un factor de secrecion de proteinas con alta eficacia secretora y un vector de expresion que lo comprende.
MX2018001055A (es) Promotores para mejorar la expresion en poxvirus.
WO2016116905A9 (en) Cmv antigens and uses thereof
MX369776B (es) Vectores recombinantes del virus isfahan.
HK1245809B (zh) 通過融合到來自七鰓鰻的序列進行的重組蛋白多聚化
PH12019500578A1 (en) New promoters
ZA201603187B (en) Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors
MX2019004183A (es) Secuencia de nucleotidos que expresa una proteina de anclaje a exosoma para su uso como vacuna.
NZ603431A (en) Parapoxvirus vectors containing rabies virus antigen
SG11201808266QA (en) Hepatitis b treatment vaccine on the basis of inactivated, fully recombinant hansenula cells expressing hbsag
MX2021009154A (es) Selectividad eficaz de proteinas recombinantes.
MX2017004769A (es) Elementos promotores y reguladores para mejorar la expresion de genes heterologos en celulas hospederas.